Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
OtherShort Communication

EVIDENCE FOR THE VALIDITY OF CORTISOL 6β-HYDROXYLATION CLEARANCE AS A NEW INDEX FOR IN VIVO CYTOCHROME P450 3A PHENOTYPING IN HUMANS

Takashi Furuta, Atsushi Suzuki, Chieko Mori, Hiromi Shibasaki, Akitomo Yokokawa and Yasuji Kasuya
Drug Metabolism and Disposition November 2003, 31 (11) 1283-1287; DOI: https://doi.org/10.1124/dmd.31.11.1283
Takashi Furuta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsushi Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chieko Mori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiromi Shibasaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akitomo Yokokawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuji Kasuya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

This study uses stable isotope methodology to evaluate the validity of 6β-hydroxylation clearance of endogenous cortisol as a new index for in vivo CYP3A phenotyping in humans. Important factors contradictory to the use of a conventional index of urinary ratio of 6β-hydroxycortisol to cortisol (6β-OHF/F) to evaluate in vivo CYP3A activity are also discussed. Stable isotopically labeled cortisol (3-5 mg) was orally administered to three healthy adult subjects to accurately determine the fractional metabolic clearance specific for the 6β-hydroxylation of cortisol. Plasma concentrations of labeled cortisol and urinary excreted amounts of labeled cortisol and 6β-OHF were analyzed by gas chromatography-mass spectrometry simultaneously with their endogenous counterparts. There was a good correlation between endogenous and exogenous 6β-hydroxylation clearances in the three subjects tested (r = 0.7733, 0.9112, and 0.9534 for 2-, 4-, and 6- to 8-h urine collection periods, respectively). This strongly suggests that the endogenous 6β-hydroxylation clearance can be used as an appropriate index for phenotyping the in vivo CYP3A activity. Furthermore, observed intra- (2.1- to 4.6-fold) and interindividual variabilities (ca. 5-fold) in the labeled cortisol renal clearance suggest that the urinary ratio 6β-OHF/F, a function of 6β-hydroxylation clearance and renal clearance of cortisol, does not always reflect the in vivo CYP3A activity. When a macrolide antibiotic, clarithromycin, was administered to a healthy volunteer in a dose of 200 mg every 12 h for 6 days, the inhibitory effects of clarithromycin on the in vivo CYP3A activity were clearly seen by the 6β-hydroxylation clearance of endogenous cortisol but not by the urinary ratio 6β-OHF/F.

Footnotes

  • ↵1 Abbreviations used are: P450, cytochrome P450; F, cortisol; 6β-OHF, 6β-hydroxycortisol; 6β-OHF-d5, 6β-[1,1,19,19,19-2H5]hydroxycortisol; cortisol-d5, [1,1,19,19,19-2H5]cortisol; cortisol-13C4, [1,2,4,19-13C4]cortisol; CLm(6β)-exo, 6β-hydroxylation clearance of exogenous (labeled) cortisol; X(6β)-exo, urinary excretion amount of exogenous (labeled) 6β-hydroxycortisol; AUC(F)-exo, area under the curve of exogenous (labeled) cortisol; X(F)-exo, urinary excretion amount of exogenous (labeled) cortisol; CLr(F), renal clearance of cortisol; CLr(F)-exo, renal clearance of exogenous (labeled) cortisol; CLm(6β)-endo, 6β-hydroxylation clearance of endogenous cortisol; X(6β)-endo, urinary excretion amount of endogenous 6β-hydroxycortisol; AUC(F)-endo, area under the curve of endogenous cortisol; X(F)-endo, urinary excretion amount of endogenous cortisol; CLr(F)-endo, renal clearance of endogenous cortisol.

  • This work was supported in part by a Grant for Private Universities provided by the Promotion and Mutual Aid Corporation for Private Schools of Japan. This study was presented in part at the 16th Annual Meeting of Japanese Society for the Study of Xenobiotics, Kobe, Japan, October 17-19, 2001.

    • Received March 24, 2003.
    • Accepted July 23, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 31 (11)
Drug Metabolism and Disposition
Vol. 31, Issue 11
1 Nov 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
EVIDENCE FOR THE VALIDITY OF CORTISOL 6β-HYDROXYLATION CLEARANCE AS A NEW INDEX FOR IN VIVO CYTOCHROME P450 3A PHENOTYPING IN HUMANS
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherShort Communication

EVIDENCE FOR THE VALIDITY OF CORTISOL 6β-HYDROXYLATION CLEARANCE AS A NEW INDEX FOR IN VIVO CYTOCHROME P450 3A PHENOTYPING IN HUMANS

Takashi Furuta, Atsushi Suzuki, Chieko Mori, Hiromi Shibasaki, Akitomo Yokokawa and Yasuji Kasuya
Drug Metabolism and Disposition November 1, 2003, 31 (11) 1283-1287; DOI: https://doi.org/10.1124/dmd.31.11.1283

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherShort Communication

EVIDENCE FOR THE VALIDITY OF CORTISOL 6β-HYDROXYLATION CLEARANCE AS A NEW INDEX FOR IN VIVO CYTOCHROME P450 3A PHENOTYPING IN HUMANS

Takashi Furuta, Atsushi Suzuki, Chieko Mori, Hiromi Shibasaki, Akitomo Yokokawa and Yasuji Kasuya
Drug Metabolism and Disposition November 1, 2003, 31 (11) 1283-1287; DOI: https://doi.org/10.1124/dmd.31.11.1283
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preincubation Effects on Inhibition of OCT1 by CsA
  • Carbamazepine Metabolite and Hypersensitivity Reactions
  • SULT4A1 Preserves Mitochondrial Function
Show more Short Communications

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics